NovoCure's Total Assets for the quarter that ended in Jun. 2023 was $1,159.0 Mil.
Warning Sign:
If a company builds assets at 24.2% a year, faster than its revenue growth rate of 21.8% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, NovoCure's average Total Assets Growth Rate was 1.90% per year.
During the past 3 years, the average Total Assets Growth Rate was 13.20% per year.
During the past 5 years, the average Total Assets Growth Rate was 24.20% per year.
During the past 10 years, NovoCure's highest 3-Year average Total Assets Growth Rate was 75.10%. The lowest was 13.20%. And the median was 35.30%.
Total Assets is connected with ROA %. NovoCure's annualizedROA % for the quarter that ended in Jun. 2023 was -19.69%. Total Assets is also linked to Revenue through Asset Turnover. NovoCure's Asset Turnover for the quarter that ended in Jun. 2023 was 0.11.
NovoCure Total Assets Historical Data
The historical data trend for NovoCure's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
NovoCure Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Total Assets
339.79
479.45
1,051.98
1,139.50
1,191.65
NovoCure Quarterly Data
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Total Assets
1,162.67
1,174.22
1,191.65
1,174.34
1,159.02
NovoCure Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
NovoCure's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Net Income data used here is four times the quarterly (Jun. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
NovoCure's Asset Turnover for the quarter that ended in Jun. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
NovoCure Total Assets Related Terms
Thank you for viewing the detailed overview of NovoCure's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. Products are comprised of two main components: electric field generator and arrays and related accessories. NovoCure derives its major revenues in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
0.25(1.45%) Volume: 1,712,176 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NVCR has been successfully added to your 
